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Background: Dysfunctional mitochondrial processes limit malignant cells ability to use energy from fatty acids and
ketones. Animal studies using ketogenic diets for cancer show encouraging results. We tested the diet’s safety and
feasibility in cancer patients across a broad variety of solid tumors.
Methods: We recruited 17 advanced cancer patients who were not on chemotherapy. They consumed 20 to 40 g
of carbohydrates daily with evaluations performed weekly until week 4, then every 4 weeks until 16 weeks. Quality
of life questionnaires monitored for tolerability and compliance. Positron emission/computerized tomography was
ordered at baseline, 4,8 and 16 weeks. Student t-testing evaluated differences between baseline and last visit scores
for quality of life, weight, body mass index, and serum parameters. Correlations between weight loss and serum
ketones, glucose, lipids and creatinine were done. Two-tailed unpaired t-testing of the mean weight loss compared
responders against non-responders.
Results: Eleven out of seventeen enrolled patients were evaluable. Mean age was 65+/- 11.7 years, weight 203 +/-
4.98 lbs. (92 ± 2.3 kgs.) and previous treatment failures was 1.7, +/- 0.97. All lost significant weight with hematologic,
biochemical and lipid tests remaining stable. Quality of life scores slightly improved. At 4,8 and 16 weeks, six (54.5 %),
five (45.4 %) and four (36 %) patients were stable or improved. We observed no correlations between serum glucose,
ketones or lipids. Clinical response did not correlate with ketosis or glycemia. Responders (stable disease or partial
responders) lost statistically more weight than non-responders. Dietary compliance was difficult. Only three patients
continued dieting past 16 weeks. Out of these, two patients developed brain metastases and were on steroids.
They survived 80 and 116 weeks respectively. The third patient underwent residual tumor resection and has no
disease at 131 weeks.
Conclusions: Modified Atkins diets are safe and feasible in advanced cancer. Quality of life was preserved.
Patients who lost at least 10 % of their body weight responded the best. Steroid intake affected optimal ketone
and glucose levels. Despite this, survival improved in some melanoma and lung cancer patients. Further studies
are recommended.
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Emerging evidence indicates that ketogenic diets can
have therapeutic potential for a broad range of cancers
in preclinical animal models and in patients [1–6]. A
ketogenic diet is a high-fat low carbohydrate diet that
was developed originally to treat refractory epilepsy [7].
KDs create a metabolic state similar to that seen in
water-only fasting, where blood glucose levels are re-
duced and blood ketone bodies (D-β-hydroxybutyrate
and acetoacetate) are elevated [7, 8]. Warburg first
showed that aerobic fermentation (lactate production
in the presence of oxygen) was a hallmark feature of
many cancers [9]. This unusual metabolism of tumor
cells later became known as the Warburg effect [10].
Aerobic fermentation was considered a compensatory
response to an underlying deficiency in oxidative phos-
phorylation that could arise from any number of deficien-
cies in the structure, function or number of mitochondria
[11]. Consequently, many tumor cells become addicted to
glucose for survival and growth [8, 12, 13]. KDs could
therefore put tumor cells under metabolic stress in
lowering the availability of glucose and in elevating
blood ketone bodies that require functional mitochon-
dria for metabolism [13, 14].
Most normal cells of the body readily metabolize
ketone bodies for energy especially when glucose levels
become reduced. Indeed, ketone bodies are considered a
super fuel since they enhance the ΔG of Adenosine tri-
phosphate ATP hydrolysis while reducing production of
reactive oxygen species (ROS) through the co-enzyme Q
couple [15]. In contrast to normal cells, the glucose-
dependent tumor cells cannot use ketone bodies effect-
ively for energy [16]. Ketone bodies can increase ROS in
tumor cells, which can be lethal to these cells [2]. Hence,
diets that can target glucose availability while elevating
circulating ketone bodies can be a non-toxic therapeutic
strategy for managing those tumor cells that express the
Warburg effect.
The present study was conducted to evaluate the safety
and tolerability of a modified Atkins diet on subjects with
advanced cancers. Our secondary objective was to de-
termine whether the diet influenced tumor stability or
progression based on changes in fluorodeoxyglucose
FDG and PET/CT imaging.
Methods
Recruitment and eligibility
This study was reviewed and approved by our hospi-
tal’s Independent Review Board (IRB) and listed on -
(https://clinicaltrials.gov/ct2/show/results/NCT01716468,
Ketogenic Diet in Advanced Cancer). Patients were re-
cruited from the Hematology Oncology outpatient clinic
of the PittsburghVeteran Affairs Healthcare System (Pitts-
burgh, PA). All patients had advanced solid malignanciesthat were measurable and avid on FDG PET/CT imaging.
None were on chemotherapy at the time of enrollment,
and all had good performance status (ECOG 0–2). Exclu-
sion criteria included cases of active gout or kidney stones,
active cardiac disease, cachexia, poorly controlled diabetes,
liver dysfunction (alanine/aspartate aminotransferase)
ALT/AST >3 x upper limits of normal (ULN) if with liver
metastasis and > 5 x ULN if no liver metastases), renal
failure (serum creatinine of > 2.0 mg/dl) or known brain
metastatic disease.
Study details
Primary endpoint was safety and feasibility. We investi-
gated quality of life parameters and used a modified
Atkins diet as the standard diet for this trial. Patients
were allowed 20 to 40 g of carbohydrates per day, during
a two-day screening period and were advised on grocery
shopping, and menu planning. We restricted consump-
tion of high carbohydrate foods such as cereal, bread,
rice, pasta, potatoes and all fruits, but did not restrict
calories, protein or fats (Table 1).
Declining performance status, worsening disease,
grade 3-weight loss, or inability to maintain at least trace
ketosis were criteria for removal. Eligible patients were
evaluated at weeks 4, 8, 12 and 16 or until disease pro-
gression or voluntarily termination. Patients used ver-
sion three of the European Organisation for Research
and Treatment of Cancer Quality of Life Questionnaire-
c30 (EORTC QLQ-c30). Periodic history and physical
examinations included measures of height, weight and
blood pressure. Blood was drawn (5 cc.) at mid-morning
(between 10 AM-12 noon) during the appointed visit
days, and was evaluated for a complete blood count,
metabolic panel 14, (including electrolytes, uric acid,
renal, liver and cholesterol profile), and for serum
ketone/beta-hydroxybutyrate determinations. All blood
specimens were processed in the clinical pathology la-
boratory (Pittsburgh VA Healthcare System) using 0.4 cc
in Beckman DXC800 and DXH800 chemistry and cell
hematology analyzers. Patients were monitored for ad-
verse effects and diet tolerability. Tumors were evaluated
using PET /CT for heat imaging and RECIST version 1.1
criteria for size.
PET/CT scanning technique
All patients with fasting blood glucose levels from 60 to
180 mg/dl were included in the study group. The
patients received between 10–15 mCi of FDG intrave-
nously, (~0.15 mCi/kg BW). An in-vivo incubation time
of 60 min was allowed for optimal FDG accumulation to
be seen in the tumor’s hypermetabolic areas. CT-PET
imaging was performed on a Philips-Gemini TF PET
scanner. Time-of-Flight 3-D acquisition involved: 50 %
bed position overlap with acquisition time of 1.75 min
Table 1 Modified Atkins Diet
Food category Allowed Prohibited
Fruits None All, fresh, dried, canned.
Beverage water, diet drinks or diet sodas, liquor, black coffee, tea,
tonic water, broth
Wine, beer, milk, fruit juices, regular soda
Vegetables green leafy vegetables,cucumbers, celery, cauliflower, brussel
sprouts, broccoli, mushrooms, onions, peppers, kale,
spinach, asparagus, 5 olives a day.
Carrots, Potatoes, Squash, Beans, Tomatoes,
corn, peas, squash, sauerkraut
Meats and
protein
Beef, pork, poultry, turkey, lamb, venison, game fowl, fish, clams,
lobster, shrimp, scallops, deli meats, bacon, lunchmeat, eggs,
sliceable cheese, sour cream, cream cheese, block cheese
Breaded meats or breaded fish products, soft cheeses,
processed cheese products, milk, yogurt
Miscellaneous Salt, pepper, spices, splenda, aspartame
Oil, lemon juice, ghee, coconut oil, butter,
full cream, nuts (small amounts), pork rinds, canola oil,
real mayonnaise, oils (limit to 2 T or <4 g of carbohydrate
Oil based salad dressings
Sugar, honey, molasses, sugar alcohols, juices,
maple syrup, catsup, prepared salad dressings with
added sugar, fructose, corn syrup, sugar free candy
or chocolates fat free dressing, low fat dairy products,
peanut butter, ice cream, chips, cream based dressings
Breads, pastries
and cereals
None All rice, cereals, grains, breads, flour products, popcorn, chips,
pretzels, pancakes, muffins, bagels, waffles cakes, pies.
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PET scans were obtained with standard established
protocol parameters from skull base to thigh level and/
or whole body as needed. Acquired CT and PET images
were processed to generate 3-plane images, MIP images,
and co-registered series. The studies were interpreted
and compared to prior evaluations using a Philips EBW-
PET workstation. Tumor size was evaluated in two di-
mensions on axial images. Standardized uptake values
(SUV) were recorded for each area and were compared
to the same area in subsequent studies. Liver SUV near
the falciform ligament was used as internal control.
Statistical and graphical analysis
The EORTC QLQ-c30 was used to assess quality of life
(QOL) scores. Scores were compiled and a line graph
was created depicting QOL over specific time points
(baseline, and at weeks 4, 8 and 16) Fig. 2. The student
t-test was used to evaluate the significance of differences
between baseline scores and last visit scores for quality of
life QOL, body weights, and body mass index (BMI).
Comparisons between baseline and last visit values were
also evaluated for the following blood markers: total chol-
esterol, the high and low density lipoproteins (HDL and
LDL), triglycerides, fasting glucose, serum creatinine,
white blood cell count (WBC), uric acid, albumin, and
serum b-hydroxybutyrate (βOHB). Correlations were
evaluated between net body weight loss and the follow-
ing serum markers: serum beta-hydroxybutyrate/ke-
tone levels, glucose, and creatinine. Correlations were
also calculated between serum glucose and βOHB and
between glucose versus total, HDL, LDL cholesterol
and triglycerides. Two-tailed unpaired t-testing of the
mean weight loss in responders versus non-responders
(SD or PR) was performed using IBM SPSS Statistics
Version 21 software. Testing was also performed usingvalues of ketone βOHB and glucose levels. SUV lesion
values of responders were compared with the values
from non-responders.
Results
Recruitment and initial screening process
Demographics
Over 300 prospective candidates for the study were
screened by phone, email, and in person. All 17 of the
accepted candidates were Caucasian males, and were re-
cruited from the Pittsburgh Veteran Affairs Hematology
and Oncology outpatient clinic. The average age was 65
with a median age of 64 (42–87 years). Demographics
are listed under Table 2. All patients were overweight
(203 ± 4.98 lbs. or 92 ± 2.3 kgs.) and had a mean body
mass index (BMI) of 29.46 ± 5. Tumor histology was
diverse and included adenocarcinoma (biliary, prostate,
colon, pancreas-2, lung; 6 patients), squamous cell car-
cinoma (lung, parotid, glottis; 4 patients), malignant
melanoma (3 patients), brain tumors (glioblastoma and
astrocytoma; 1 patient each), papillary thyroid carcinoma
(1 patient), and hepatocellular carcinoma (1 patient). All
malignancies were advanced, metastatic, and unresect-
able. All but three were pretreated. The mean number
of previous treatment failures was 1.7. Three patients
were chemo-naïve (patients 4, 15 and 17) and declined
chemotherapy.
Screen failures and dietary adherence: Screen failures
occurred in 6/17 (35 %) patients. Patient #1 withdrew
after two weeks due to personal issues. Patients # 2, #14,
and #15 withdrew within one week due to deteriorating
performance status unrelated to the diet. Patient #2 was
an insulin dependent diabetic, but no longer required in-
sulin after only 2 days of dieting. Patient #11 did not
qualify due to absence of hyper-metabolic activity on his
PET CT scan. Patient # 16 changed his mind regarding
Table 2 Patient Demographics
Age /Sex Race Body mass index Diagnosis Previous treat ment Histology
1 64 Male Caucasian 32 Bile ducts 3 cholangiocarcinoma
2 64 Male Caucasian 27 Brain cancer 2 Grade 4 glioblastoma
3 66 Male Caucasian 40 Prostate 2 adenocarcinoma
4 87 Male Caucasian 37 Skin cancer 0 melanoma
5 67 Male Caucasian 24 Renal cell 3 Clear cell
6 65 Male Caucasian 27.5 Pancreatic 2 Adenocarcinoma
7 66 Male Caucasian 25.5 Colon cancer 2 Adenocarcinoma
8 64 Male Caucasian 34 Thyroid 2 Papillary
9 62 Male Caucasian 30 Skin cancer 2 Melanoma
10 82 Male Caucasian 31 Parotid gland/Head/neck 1 Squamous cell cancer
11 49 Male Caucasian 27 Brain cancer 2 Astrocytoma
12 42 Male Caucasian 29 Skin cancer 2 Melanoma
13 59 Male Caucasian 25 Head/neck supraglottic 2 Squamous cell
14 66 Male Caucasian 35 Liver 1 Hepatocellular carcinoma
15 54 Male Caucasian 26 Pancreatic 0 Post lung transplant,
Adenocarcinoma
16 68 Male Caucasian 24 Lung 0 Squamous Non small cell
17 84 Male Caucasian 23 Lung 0 Adenocarcinoma Non small cell Stage 4
Table 3 Adverse Effects
Adverse Effects n = 11 Number of patients Percentage
Weight loss 8 73 %
Hyperuricemia 7 64 %
Hyperlipidemia 2 18 %
Pedal edema 2 18 %
Anemia 2 18 %
Halitosis 2 18 %
Pruritus 2 18 %
Hypoglycemia 2 18 %
Hyperkalemia 2 18 %
Hypokalemia 2 18 %
Hypomagnesemia 2 18 %
Flu-like symptoms/fatigue 2 18 %
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(65 %) had a mean age of 65 ± 11.7 years, weight 203 ±
4.98 lbs. These eleven proceeded with the trial, complet-
ing between 4 to 16 weeks of dieting without significant
adverse effects. Six patients (35 %) maintained the diet for
8 weeks and four patients (23 %) (# 4,9,12,17) completed
16 weeks. Of these four, only three (# 4,9 and 12) success-
fully dieted beyond 16 weeks. One patient (# 4) remained
very active until he died at 80 weeks, another patient (#9)
who also remained active died suddenly at 116 weeks.
The third patient (#12) remains alive without evidence
of disease at 131 weeks.
Adverse effects
No significant adverse effects were observed in any of
treated patients. Indeed, a slight trend for improved
quality of life was noted for most patients on the diet.
Weight loss was observed in 8/11 patients (73 %). Hy-
peruricemia was observed in 7/11 patients (64 %), and
hyperlipidemia in 2/11 patients (18). Pedal edema,
anemia, halitosis, pruritus, hypoglycemia, hyperkalemia,
hypokalemia, hypomagnesemia, fatigue and flu like
symptoms were seen in 2/11 patients (18 %). Although
2 patients reported halitosis, only one was determined
to be actually with ketone breath (Table 3).
Effect on weight, body mass index (BMI), and blood pressure
A mean weight loss of 3.2 lb. (1.5 kgs.) wt. loss (-1.5 %),
median 3.5 SD 4.92, range 17;–11 to +6 lb. (-5 kg. to +
2.7 kg) was observed after only 2–3 days of dieting.Weight loss was consistent during the study and by
week 16, subjects had lost 27 lbs. ± 13.3 or 12.3 ± 6.0
kgs. (-13 %) (Table 3, Fig. 1). Weight loss for all subjects
was 16.4 ± 12.8 lbs (7.5 ± 5.8 kgs.) and highly significantly
reduced compared to baseline values (P < 0.000108)
Table 4. Three patients dieted for 16 weeks and beyond
with a median percent weight loss of 10.19 % (range 6.91–
17.83). BMI was also significantly decreased (P < 0.0004)
compared to baseline values with a mean difference of
2.669 ± 1.99, (Fig. 1 : Body mass index and weight changes
over time) (Table 4).
Fig. 1 Body mass index and weight changes over time; Significant decreases in body mass index and body weight were seen when comparing
baseline values versus final visit values
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compared to last visit values
No significant differences were seen between initial values
and last visit values for biochemical and hematologic
parameters (Table 5). Blood glucose values were similar
at the start and at the end of the study with mean
values of 92.8 ± 30 mg/dl (5.2 mM). One patient (#2)
was an insulin-dependent type 2 diabetic and experienced
a 100 % decrease in insulin requirements after two days
on the diet and remained asymptomatic.
Lipid profiles of almost all patients (94 %) remained
stable throughout and did not change significantly from
baseline to last visit. Total cholesterol (p = 0.819), LDL
cholesterol (p = 0.772), HDL (p = 0.0612), triglyceride
(p = 0.674) values at the last visit did not significantly
change from baseline. Although the majority of the pa-
tients had no change in their lipid profiles, patient #12
started the trial with an elevated LDL value of 191 mg/dl,
which decreased to 112 mg/dl by week 16 without
using lipid lowering medication. The reverse was seenTable 4 Weight loss at time periods 4,8,12 and 16 weeks
2–3 days Week 4 Week 8 Week 12 Week 16
Mean 3.2 lbs. 13.9 lbs. 21 lbs. 23 lbs. 27 lbs.
Weight loss (lbs.) (1.5 kg.) (6.3 kg.) (9.5 kg.) (10.5 kg.) (12.3 kg.)
% weight loss −1.5 % - 7 % - 10 % 11 % 13 %
Standard deviation ±4.92 ± 4.84 ± 7.42 ± 5.35 ± 13.3with patient # 9. This patient started with a fasting
LDL of 85 mg/dl and had an LDL level of 178 by week
16, necessitating initiation of a statin medication. Blood
urea nitrogen (BUN)/creatinine ratios (p = 0.108), serum
creatinine (p = 0.314), albumin (p = 0.698), and uric acid
levels (p = 0.565) all remained stable. White blood cell
counts at baseline did not significantly differ with last visit
values. Baseline PET/CT mean calculated SUV values for
all lesions compared to week 4 and 8 values remained un-
changed (p = 0.433 and p = 0.872 respectively). Mean SUV
baseline values compared to last visit SUV also did not dif-
fer (p =0.77) There were no statistical difference systolic
(p = 0.394) and diastolic (p = 0.43) blood pressure readings
at baseline versus last visit (Table 5).
Glucose/ketone index
The Glucose/Ketone Index (GKI) is a ratio of the glucose
(mmol) over beta-hydroxybuytrate levels (mmol) at any
given time [13]. As levels of blood glucose decline, the
blood levels of ketone bodies should rise, intersecting at a
certain point beyond which one enters the “therapeutic
zone”. This is when tumor growth is expected to slow or
cease. None of the patients in this study reached GKI
values predicted for therapeutic benefit against cancer
(<1.0). Elevated β −OHB levels were observed in all pa-
tients within the first two days of dieting. In the first two
days of dieting, 7 out of 10 patients (70 %) easily achieved
a ketosis levels of 3-10 mg/dl or 0.3–1.0 mM, and only 2
Table 5 Biochemical and hematologic parameters; Standardized Uptake Values (SUV), (Initial versus last visit)
Parameter Mean Baseline Standard Deviation Mean Last Visit Value Standard Deviation Significance
Weight (lbs.) 210 (95 kg) 41.26 (18.7 kg) 193 (87.7 kg) 37.82 p = 0.0001
BMI 30.3 5.29 27.7 4.69 p = 0.001
Glucose (mg/dl) 89 14.8 97.1 12.07 p = 0.944
BHB 11.5 10.27 9.14 8.73 p = 0.785
BUN/Creatinine ratio 18.17 5.76 16.8 6.46 p = 0.108
Serum creatinine 1.14 0.23 1.09 0.21 p = 0.314
Systolic BP 125 10.35 127 15.59 p = 0.394
Diastolic BP 70 11.27 77 5.57 p = 0.043
Total Cholesterol 179 34.6 186 56.4 p = 0.819
LDL Cholesterol 125 37.6 119 40.76 p = 0.772
HDL Cholesterol 38.7 15.09 46.75 24.4 p = 0.0612
Triglycerides 114 44.45 103.58 47.70 p = 0.674
Uric Acid 6.34 1.42 5.92 1.73 p = 0.565
WBC count 7.06 4.84 7.17 3.98 p = 0.867
ALT 28 11.34 25 13.78 p = 0.193
Albumin 3.67 0.63 3.71 0.84 p = 0.698
SUV 2.87 1.44 2.75 1.62 p = 0.689
BMI Body Mass Index, BHB beta-hydroxybutyrate, BP blood pressure; LDL-low density lipoprotein, HDL high density lipoprotein
WBC white blood cell, ALT alanine transferase, SUV standardized uptake unit
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levels ranging from 0.3 to 4.1 mM, while the mean βOHB
level was less than 0.3 mM in the other patients. Patient
13 had some difficulty with menu planning and was re-
moved from the trial when he progressed at 4 weeks,
achieving only 2 weeks of ketosis out of 4. Once ketosis
was achieved, mean ketone levels remained unchanged
till the last visit compared to the first positive baseline
(p = 0.785). After only two days of fasting the mean
βOHB level rose to about 11.3 mg/dl (1.1 mM) with
patients 5,6,7,8 and 12 having registered serum ketosis
of over 19 mg/dl or 1.83 mM (median 24, range 19–26
mg/dl or 1.83 mMol to 2.5 mM). With the exception of
patient #8, all the other patients maintained this level
of ketosis for the first 4 weeks. As the study progressed,
a drop in serum ketone levels was seen. The mean at
week 4 was 12.08 mg/dl ± 10, and declined to 7.4 mg/
dl ± 4.81, and 6.17 mg/dl ±7.99 at weeks 8 and 16,
respectively. This decrease in mean βOHB was not sta-
tistically significant (p = 0.875) indicating generally
good compliance and ability to maintain ketosis with the
passage of time. Note, that when converted to millimoles,
the achieved values of 7 eligible patients (63 %) ranged
between 0.28 mM to 0.96 mM ketones with 4 patients
(36 %) achieving values between 0.96 to 4.13 mM.
Correlations between weight loss and serum chemistries
Non-significant differences were seen with net weight
loss (lbs.) versus βOHB ketones (p = 0.325, p = 0.992,p = 0.897), glucose (p = 0.95, p = 0.295, p = 0156), or
creatinine (p = 0.425, p = 0.441, p = 0.377) at weeks 4,
8, and 16 (Table 6).Correlations between serum glucose and chemistries
At 4 and 8 weeks, no significant correlations were found
between serum glucose versus percent (%) weight loss,
ketone levels, triglycerides (TG), low density lipoprotein
(LDL), high density lipoprotein (HDL), and total choles-
terol (Table 7).Quality of life parameters
Patients who continued on the diet for 4 weeks or more
(n = 6) reported stable well-being and symptomatology
at end of their trial with no statistically significant deteri-
oration in quality of life scores: social (p = 0.179), physical
(p = 0.225), emotional (p = 0.313), financial difficulties
(p = 0.347), cognitive (p = 0.195) and role (p = 0.859)
functioning. There was also no significant worsening of
fatigue (p = 1.00), insomnia (p = 0.798), appetite (p = 0.269),
constipation (p = 0.343), diarrhea (p = 0.347), or pain
(p = 0.262).
Patients reported some improvement of cognitive
functioning, dyspnea, constipation, diarrhea and insomnia.
At 4 weeks there was a slight increase in the fatigue score
but this also improved by 8 and 16 weeks (Fig. 2: Quality
of Life parameters).
Table 6 Correlations between net weight loss and serum
chemistries
Test Week 4 Week 8 Week 16
βOHB (serum)
Beta hydroxybutyrate
p = 0.325 p = 0.992 p = 0.897
Fasting glucose p = 0.95 p = 0.295 p = 0.156
Serum creatinine p = 0.425 p = 0.441 p = 0.377
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Two-tailed unpaired t testing of the mean weight loss in
non-responders versus responders was performed using
SPSS (Statistical Package for the Social Sciences) and
Graphpad software 2015. The percentage body weight
loss was significantly greater in the responders (stable
disease SD or partial response PR) (p = 0.03, SD ± 2.28)
than in the non-responders. No differences were seen
between responders and non-responders in terms of serum
ketone values (p = 0.67), fasting glucose (p = 0.1905), or
mean calculated SUV (p = 0.7714).
Effect on the tumor
Due the low patient number, statistical analysis of the
diet’s effect on tumor growth could not be performed.
At the 4-week assessment, five (45 %) progressed (pa-
tients 3, 5, 6,10,13) based on RECIST 1.1 criteria and 6
(54.5 %), (patients 4,7,8,9,12,17) had stable or partially
improved disease. One patient (# 5) had stable disease
(decreased 3.9 %) in his target lesions at week 4 and
achieved excellent ketosis (+3), but was considered pro-
gressed and had to be removed from the trial due to a
newly discovered brain metastasis. Whether it was
present at the beginning of the trial or was a new lesion
was undetermined since he did not have baseline head
scans. All the other six stable patients were allowed to
diet until 8 weeks. At 8 weeks, one patient (# 7) had
progressive disease, but five patients remained stable (#
4, 8, 9,12, 17) or with diminished disease. Patient # 8
withdrew voluntarily, but 4 patients (# 4, 9, 12, and 17)
continued dieting until 16 weeks. At 16 weeks, four pa-
tients (36 % of total, 100 % of 8th week responders) had
stable disease (# 12, 16, 17) or reduced disease symptoms
(# 9) at the end of their trial participation (Table 8).Table 7 Correlations between serum glucose and weight,
ketones, and lipid parameters
Test Week 4 Week 8
% weight loss p = 0.113 p = 0.435
BHB ketones p = 0.365 p = 0.89
Triglycerides p = 0.169 p = 0.88
LDL low density lipoprotein p = 0.364 p = 0.364
HDL high density lipoprotein p = 0.557 p = 0.66
Total cholesterol p = 0.75 p = 0.42All four patients who continued the diet past 16 weeks
were followed in the outpatient clinic and by telephone
interview. One out of the four, suffered from a case of
stage IV lung cancer. The remaining three patients all
had stage IV malignant melanoma, one of whom (# 12)
was BRAF V600 positive.
The first 16-week patient (# 4), an 87-year-old male
with diffuse multi-organ involved Stage IV melanoma,
refused all forms of chemotherapy, but agreed to enroll
in the modified Atkins diet trial. At 4 weeks of dieting
he felt energetic and remained asymptomatic. His 4-
week PET/CT scan showed mixed findings with several
areas showing decreased as well as increased FDG
activity. The overall clinical picture for this patient
showed improved disease. By 8 and 16 weeks his dis-
ease remained stable. After 16 weeks he dieted with
occasional lapses in ketosis. He developed brain metas-
tases after 36 weeks from enrollment and was treated
with steroids and gamma knife irradiation. He had dif-
ficulty maintaining ketosis but maintained his weight
and active lifestyle while pain free until a few weeks
before his death at age 88, marking 80 weeks from his
date of enrollment.
Our second patient, (# 9), was a 62 year old male with
stage IV melanoma who completed the trial at 16 weeks
with stable disease. Intermittently he would be less strict
with the diet and lapse out of ketosis. He had tried and
progressed through ipilimumab, pembrolizumab, three
rounds of transhepatic chemoembolization, two rounds
of oral Temozolomide, and gamma knife radiation to his
brain metastases. During the last year of his life he re-
ceived no chemotherapy other than gamma knife brain
irradiation plus a month of Temozolomide, and followed
the ketogenic diet as his main treatment course. He was
hospitalized for new onset seizures and subsequently
placed on systemic steroids. Despite this he mostly
remained on the ketogenic diet but because of the
hyperglycemic effects of the steroids was unable to
achieve the target glucose ketone index GKI. His per-
formance status however remained excellent and he
lived a total of 116 weeks from diet initiation, and
nearly three years from his initial diagnosis of stage
four melanoma.
Our third patient, a 42-year old male with stage IV
BRAF V600 positive, Vemurafenib intolerant metastatic
melanoma (patient 12), completed 16 weeks of the trial
with stable disease but had persistently PET positive left
axillary nodes which had not changed in size but did
have some partial decrease in hypermetabolic activity
while on the diet. He underwent complete surgical re-
moval of his persistent bulky metastatic axillary nodes
in July 2014 and had no adjuvant chemotherapy or ra-
diation. He followed the modified ketogenic diet for an-
other year after surgery and then reverted back to a
Fig. 2 Quality of Life parameters; Scores were obtained using EORTC QLQ-c30 questionnaires. These scores were plotted against time and
although there was a trend towards improvement in quality of life parameters, these differences were not statistically significant
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of disease on PET/CT scan and remained alive and well
at 131 weeks.
The fourth patient, patient 17, an 84 year old with
chemo-naive stage IV squamous cell lung carcinoma
dieted until 16 weeks and finished the trial with stable
disease while achieving excellent ketosis (+2). However,
after completing the trial at week 16, he decided to
revert back to low carbohydrate, non-ketotic diet. He
failed to follow up for repeat imaging and died at
40 weeks.
Discussion
This trial showed that a modified ketogenic diet was well
tolerated in cancer patients with a broad variety of solid
tumors. Adverse effects were minimal and none were
serious. These findings are therefore consistent with
other studies that treated brain cancer patients with ke-
togenic diets [4, 5, 11, 14, 16, 17, 18] Concerns about
weight loss and malnutrition were one of the initial wor-
ries as was the possibility of deleterious effects on one’s
lipid profile and quality of life. Most of our patients were
either overweight (7 pts. or 42 % with BMI 25–29.9) or
obese (7 or 42 % with BMI over 30) at enrolment and
only 3 had normal (18 % with BMI 18.5–24.9) weight
upon entering the trial. Surprisingly, weight loss did notshow significant correlations with ketone levels, glucose
or other hematologic or electrolyte measurements.
Weight loss was seen in all patients and was significant
(p = 0.0001). The patients who responded with either
stable disease or partial responses had significantly more
weight loss (p = 0.01) than those patients who pro-
gressed. Weight loss percentage of at least 10 % or
more was seen in the responders. This weight loss was
not like the cachectic weight loss that we see in cancer
patients in their terminal stages because our patients
maintained their quality of life scores and in some cases
even improved upon them.
There was also some concern that the renal function
might worsen with this diet and that diabetics might not
be able to tolerate it. Renal function as well as hematologic
parameters remained stable. One patient (patient 4) who
began with some renal insufficiency improved his serum
creatinine after 4 weeks while another patient with dia-
betes (patient 2) who was on insulin became insulin
free within days.
Previous studies examined the effects of this diet on
small patient numbers. These studies were also of short
duration 4-12 weeks. We wanted to improve on this by
allowing our patients to diet for a longer period of time
(16 weeks). In addition we allowed long-term follow up
after the 16-week period was completed. We followed
Table 8 Diet duration, Glucose ketone index, clinical outcomes





1 Cholangiocarcinoma Less than 2 weeks NA Dropped out of study. Menu planning difficulties.
2 Glioblastoma 4 NA Progressive disease at 4 weeks.
3 Prostate cancer 4 14.30 Stable tumor size at 4 weeks, but PSA was rising;
dropped out of study
4 Melanoma 16 on trial, continued diet




Stable disease at 16 weeks, mixed findings, slow
progression, active until shortly before death at 80 weeks
5 Renal cell cancer 4 3.23 Progressive disease
6 Pancreas 4 2.06 Progressive disease at 4 weeks. Muscular body
builder habitus. Worked out daily.
7 Colon cancer 8 8.6 (week 4)
4.3 (week 8)
Stable at 4 weeks, mixed mixed CT scan findings and rising
CEA at 8 weeks.
8 Papillary thyroid 8 1.9 (week 4)
5.2 (week 8)
Stable at 8 weeks, but removed because of
grade 3 weight loss; still alive 15 months later.
Declined follow up bloodwork.
9 Melanoma 16 weeks on trial, continued




Stable disease at 16 weeks, and at 92 weeks.
Active till 2 days prior to death at 116 weeks.
10 Parotid 4 18.3 Progressed at 4 weeks. Diabetic.
11 Astrocytoma NA NA Disqualified due to negative PET scan
12 Melanoma 16, continued diet post trial
till 100 weeks. He reported at
this time that he stopped the




Stable at 16 weeks. Underwent metastectomy
of remaining axillary disease.
PET/CT scan no evidence of disease at 131 weeks.
13 Head and neck <4 12.14 Achieved ketosis in only 2 weeks out of 4.
Progressed at 4 weeks.
14 Hepatoma NA NA Progressed before starting diet.
15 Pancreas- post lung transplant;
on multiple immunosuppresive
anti-rejection drugs.
NA NA Very rapidly progressive disease. Progressed
before starting diet.
16 Lung cancer NA NA Had acute cardiac event and changed his mind
before starting the trial.
17 Lung cancer 16 6.1 (week 4)
5.2 (week 8)
3.2 (week 16)
Stable at 4,8 and 16 weeks. Dieted for a week
after 16, then back to standard diet. Died at 40 weeks.
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tient 17) reverted back to a standard diet within days
while the other two (patients 4 and 12) continued to
follow the diet without any subsequent chemotherapy
or radiation, remaining in stable status for as long as 80
and 131 weeks.
Combining the diet with chemotherapy and/or radiation
appears feasible. One patient (patient 9) subsequently tried
a short course (one month) of oral chemotherapy and
had also benefitted from invasive radiology as well as
radio surgical interventions.
In the VM-M3 glioblastoma model, a low GKI is related
to decreased invasion, proliferation and angiogenesis [19].
The study protocol was created prior to the introduction
of the GKI and our patients did not have the benefit of
frequent home glucose and ketone monitoring hence thecollected in-hospital glucose and ketone readings may not
be truly reflective of their actual glucose ketone indices.
Discrepancies in blood draw timing and patient compli-
ance with timing of clinic visits may have also affected
some of our glucose values. Glucose ketone indices (GKI)
were calculated and we found that although no patient
met the targeted range of GKI, some still derived benefit,
significantly outliving their estimated lifespans. One pa-
tient (patient #9) who had a good response and sur-
vived until 116 weeks, experienced persistent “ketone
breath” despite achieving low βHOB ketone readings. It
is possible that he achieved adequate therapeutic levels
that somehow escaped detection [20, 21].
We wanted to attract a diverse population of patients,
and standardize all evaluations. The small number of re-
cruited patients limited our trial, and our recruitment
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exclude diverse racial types nor exclude females. Had we
expanded our trial to another year’s length we perhaps
could have attracted a more diverse patient sample.
One previous study had recruited patients from different
institutions each with their own dietician, hence dietary
instruction was not standardized across the board [4].
Blood work/scans were sent to separate laboratories
and imaging facilities, possibly causing variations in
data interpretations. We hoped to improve on this by
recruiting all our subjects from a single institution and
uniformly obtained all our testing from our inpatient
hospital laboratory. Our images were read by a dedicated
nuclear radiologist as well as obtained via the same dedi-
cated PET/ CT scanner. Travel time was also an issue.
Most of our patients lived a long distance from our hos-
pital (some > 3 h away) which made recruitment difficult
given the travel time and frequency of visits. Majority of
the interested patients who lived locally did not qualify, as
they were not US veterans, one reason for inclusion.
We chose to scan with PET/CT imaging as early as
4 weeks. Previous studies show that PET/CT scans can
detect partial responses to chemotherapy as early as after
one cycle [2]. In the future we feel that an 8 week PET/
CT scan instead of four will be more useful as some tu-
mors may actually be experiencing a tumor flare prior to
shrinkage. We also excluded patients with brain metasta-
ses because we expected poorer performance statuses. In
hindsight it could have been better to include them. Many
of these patients actually do well enough to last through a
short dietary course without any deleterious effects.
Not all of our patients responded to the KD. Previous
work on identifying characteristics that would predict
for response have studied the role of defective OXPHOS
enzymes [11, 22]. The metabolic switch from oxidative
phosphorylation to non-oxidative fermentation is thought
to be related to upregulation of transketolase TKTL-1 pro-
tein expression which was correlated with invasive tumors
[23, 24]. Identification of ketolytic and glycolytic enzyme
overexpression in malignancies may help stratify those
patients with low enzyme expression and accordingly
should respond more favorably to the KD [11, 24].
Most of our patients were overweight and were likely
to be leptin resistant and as a result have high body leptin
levels. Leptin is a pro-angiogenic metabolic hormone
which is secreted by adipose tissue. It sends satiety signals
to the hypothalamus in response to caloric intake. Ghrelin
is the opposing hormone which increases our appetite. In-
take of sucrose during the fasting state results in a rise in
serum leptin. However, over consumption of foods high in
sucrose leads to a blunted leptin response, which leads to
higher serum leptin levels [25, 26]. Unlike leptin, ghrelin
secretion is suppressed by intake of both sucrose and fats.
Leptin secretion is therefore probably linked to sucroserather than fat metabolism. Increased leptin levels are
associated with faster tumor growth in animal studies
[27]. In humans, particularly obese individuals have
higher leptin levels and correspondingly have higher
rates of human cancers. A study of melanoma patients
found significantly higher leptin levels in those with
positive sentinel node biopsies [28]. The patients who
responded with stable or improved disease lost more
percentage weight, and by doing so decreased the body
leptin and consequently slowed down angiogenesis.
The effect of the diet on lifespan cannot be adequately
examined here due to the low number of subjects en-
rolled and the diverse nature of each patient’s individual
tumors. However out of the four patients who did well
until 16 weeks, three had a diagnosis of melanoma and
all three not only went beyond 16 weeks of dieting but
also significantly exceeded their expected lifespans
(typically only 3 months). One remains alive and free
of disease at 121 weeks. Due to variations in timing of
blood draws, the reported ketone levels of these patients
were not significantly elevated and none achieved the
target glucose ketone index, although two did report
significant halitosis which could mean that their re-
corded ketone levels may be underestimating their true
average daily [20, 21] Whether patients with malignant
melanomas have intrinsic characteristics making them
more responsive to the ketogenic diet over other tumor
types remains to be investigated further.
Conclusions
The modified Atkins diet is well tolerated by patients
with advanced cancer. Hematologic parameters, serum
cholesterol, renal function and lipid levels remained
stable. There was improvement in insulin requirements
and renal function in a few patients. Quality of life mea-
sures remained stable and the diet was simple to initiate
and implement. For some, the adherence to the diet
remained excellent at one year and beyond. It is possible
that therapeutic efficacy could be greater in future stud-
ies where patients can enter the predicted GKI zone. In
this study, ideal target glucose and ketone values may
have been reached but were not accurately recorded due
to variations in patient compliance with blood draw tim-
ing and fasting states. The diet might help improve quality
and of life and enhance tumor response to chemotherapy
in cancer patients. Looking forward, the incorporation of
immunohistochemical staining for ketolytic/glycolytic
enzymes and biomarkers (i.e. leptin, insulin) and their
role in tailoring metabolic cancer management merits
further study. Notably, melanoma patients represented
the three who benefitted most from this study. Future
studies should investigate the modified Atkins diet
MAD or the ketogenic diet KD and their potential benefits
to this type of cancer.
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